相关实验视频

Updated: Jun 7, 2025

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

在透析患者中预防突破COVID-19的Tixagevimab-cilgavimab:一项前性研究

Sarinya Boongird¹, Thatsaphan Srithongkul², Sethanant Sethakarun³

¹D ivision of Nephrology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Clinical kidney journal

|November 14, 2024

概括

在接种疫苗的透析患者中,Tixagevimab-cilgavimab没有阻止突破COVID-19的发生. 然而,这种治疗在Omicron激增期间显著减少了COVID-19住院治疗.

科学领域:

免疫学免疫学免疫学
传染性疾病传染性疾病
腎臟病學 (nephrology) 是一種醫學.

背景情况:

在透析患者中,关于 tixagevimab-cilgavimab 在暴露前预防 (PrEP) 对 COVID-19 的有效性数据有限.
透析患者是一个脆弱的人群,对疫苗接种的反应可能有所减少.

研究的目的:

为了评估作为PrEP的tixagevimab-cilgavimab在接种疫苗的透析患者中的有效性.
评估 tixagevimab-cilgavimab 对突破性 COVID-19 感染和相关住院治疗的影响.

主要方法:

一项多中心前性研究招募了200名接种疫苗的透析患者.
参与者被分为一个 tixagevimab-cilgavimab 组 (150 mg/150 mg 肌内注射) 和一个对照组.
主要结局是6个月的COVID-19突破率;次要结局包括住院,ICU入院,输管和死亡率.

主要成果:

在6个月的COVID-19突破率在两组之间是相似的 (17%对15%,P=.66).
在突破性感染中,tixagevimab-cilgavimab显著减少了与COVID-19相关的住院治疗 (5.9%与40.0%,P=.02).
与tixagevimab-cilgavimab相关的不良事件是轻微的.

结论:

在Omicron激增期间,Tixagevimab-cilgavimab在接种疫苗的透析患者中没有阻止突破性COVID-19感染.
在这个高风险群体中,治疗显著减少了COVID-19相关的住院治疗.
替代性预防策略需要对透析患者进行进一步的研究.

关键词:

突破 COVID-19 的突破透析是通过透析进行的.预防预防预防预防在安全方面,安全是安全的.一个小时的时间,一个小时的时间.

更多相关视频

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

相关概念视频

Dialysis

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...